Sp-5,6-dichloro-cBIMPS (sodium salt) (Synonyms: Sp-5,6-DCI-cBIMPS) |
رقم الكتالوجGC10428 |
PKA activator
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 142439-96-1
Sample solution is provided at 25 µL, 10mM.
Ki: 30 nM
Sp-5,6-dichloro-cBIMPS is a PKA activator.
In cell biology, protein kinase A (PKA) is a family of enzymes whose activity is dependent on cellular levels of cyclic AMP. PKA is also known as cAMP-dependent protein kinase. PKA has several functions in the cell, such as regulation of sugar, glycogen, and lipid metabolism.
In vitro: Sp-5,6-dichloro-cBIMPS was found to be both a potent and specific activator of purified cAMP-PK and of cAMP-PK in platelet membranes, whereas 8-pCPT-cAMP proved to be a potent activator of cAMP-PK and cyclic-GMP-dependent protein kinase both as purified enzymes and in platelet membranes. Moreover, it was found that Sp-5,6-dichloro-cBIMPS was not significantly hydrolysed by three types of cyclic nucleotide phosphodiesterases, whereas 8-pCPT-cAMP was hydrolysed to a significant extent by the Ca2+/calmodulin-dependent phosphodiesterase and by the cGMP-inhibited phosphodiesterase. The apparent lipophilicity of Sp-5,6-dichloro-cBIMPS was higher than that of 8-pCPT-cAMP. Extracellular application of Sp-5,6-dichloro-cBIMPS to intact human platelets could reproduce the pattern of protein phosphorylation that was induced by prostaglandin E1. Additionally, in intact platelets, Sp-5,6-dichloro-cBIMPS was also more effective than 8-pCPT-cAMP in inducing quantitative phosphorylation of vasodilator-stimulated phosphoprotein, a major substrate of cAMP-PK in platelets. As demonstrated by prostaglandin E1, pretreatment of human platelets with Sp-5,6-DCl-cBiMPS Sp-5,6-dichloro-cBIMPS was able to prevent the aggregation induced by thrombin [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Sandberg, M. ,Butt, E.,Nolte, C., et al. Characterization of Sp-5,6-dichloro-1-β-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells. Biochemistry Journal 279, 521-527 (1991).
Cas No. | 142439-96-1 | SDF | |
المرادفات | Sp-5,6-DCI-cBIMPS | ||
Chemical Name | 5,6-dichloro-1-[3,5-O-[(S)-mercaptophosphinylidene]-β-D-ribofuranosyl]-1H-benzimidazole, monosodium salt | ||
Canonical SMILES | [S-][P@]1(OC[C@]2([H])[C@@]([C@@H](O)[C@H](N3C(C=C(Cl)C(Cl)=C4)=C4N=C3)O2)([H])O1)=O.[Na+] | ||
Formula | C12H10Cl2N2O5PS • Na | M.Wt | 419.1 |
الذوبان | ≤167mg/ml in ethanol;167mg/ml in DMSO;167mg/ml in dimethyl formamide | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3861 mL | 11.9303 mL | 23.8607 mL |
5 mM | 0.4772 mL | 2.3861 mL | 4.7721 mL |
10 mM | 0.2386 mL | 1.193 mL | 2.3861 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *